Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
8.07
-0.25 (-3.00%)
At close: Mar 24, 2026, 4:00 PM EDT
8.23
+0.16 (1.98%)
After-hours: Mar 24, 2026, 6:17 PM EDT
Kura Oncology Stock Forecast
Stock Price Forecast
The 8 analysts that cover Kura Oncology stock have a consensus rating of "Buy" and an average price target of $25.88, which forecasts a 220.69% increase in the stock price over the next year. The lowest target is $11 and the highest is $40.
Price Target: $25.88 (+220.69%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Kura Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 2 | 2 | 2 | 2 | 2 |
| Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 11 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $30 → $25 | Buy | Maintains | $30 → $25 | +209.79% | Mar 24, 2026 |
| UBS | UBS | Strong Buy Maintains $16 → $15 | Strong Buy | Maintains | $16 → $15 | +85.87% | Mar 13, 2026 |
| Wedbush | Wedbush | Buy Maintains $38 → $36 | Buy | Maintains | $38 → $36 | +346.10% | Mar 6, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +395.66% | Jan 13, 2026 |
| Barclays | Barclays | Buy Maintains $11 → $28 | Buy | Maintains | $11 → $28 | +246.96% | Nov 24, 2025 |
Financial Forecast
Revenue This Year
109.53M
from 67.48M
Increased by 62.31%
Revenue Next Year
173.16M
from 109.53M
Increased by 58.09%
EPS This Year
-3.22
from -3.18
EPS Next Year
-2.68
from -3.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 331.7M | 294.7M | |||
| Avg | 109.5M | 173.2M | |||
| Low | 49.0M | 59.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 391.5% | 169.1% | |||
| Avg | 62.3% | 58.1% | |||
| Low | -27.4% | -45.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.60 | -1.67 | |||
| Avg | -3.22 | -2.68 | |||
| Low | -3.77 | -3.20 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.